nim

5 P & DOCKET NO: 368-014

PATENT

JAN 3 1 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of Kinam Park, et al.

Serial No: 09/975,800 : Art Unit: Unassigned

Filed: October 11, 2001 : Examiner: Unassigned

For: PHARMACEUTICAL APPLICATIONS: OF HYDROTROPIC AGENTS, POLYMERS: THEREOF, AND HYDROGELS THEREOF:

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefor.

Inasmuch as the disclosures of U.S. Patent Nos. 4,933,643; 4,981,974; and 5,008,367 (Dandreaux et al.) are cumulative, only the last listed patent is enclosed. Inasmuch as the disclosures of U.S. Patent Nos. 4,946,967 and 4,987,210 (Login et al.) are cumulative, only the latter patent is enclosed. 37 CFR 1.98(c).

U.S. Serial No. 09/975,800

This Information Disclosure Statement is filed within three months of the filing date for this continued prosecution application (CPA) OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,

James H. Meadows, Ph.D. Reg. No. 33,965

Correspondence Address

5355 Mira Sorrento Pl.

Suite 100

San Diego, CA 92121

Tel: 619-641-8228

Fax: 503-217-9394

Date: January 18, 2002

I, James H. Meadows, hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 2023 I on 1/19/07 Signature

Please type a plus sign (+) inside this box $\rightarrow$ $+$	Patent and Trademark Offi	PTO/SB/08B (10-96) ise through 10/31/99. OMB 0651-0031 ce: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons contains a valid OMB control number.	s are required to respond to	a collection of information unless it
Substitute for form 1449A/PTO	Cor	mplete if Known
<b>{</b> }	Application Number	09/975,800
INFORMATION DISCLOSURE	Filing Date	October 11, 2001
CTATEMENT BY ABOUT AND	First named Inventor	Kinam Park

JAN 3 1 2002

Sheet

## STATEMENT BY APPLICANT

(use as many sheets as necessary) of

Application Number	09/975,800
Filing Date	October 11, 2001
First named Inventor	Kinam Park
Group Art Unit	
Examiner Name	
Attorney Docket Number	368-014

			U.S. PATENT DOCUM	1ENTS	
Examiner Initials*	Cite No.1	U.S. Patent Document Kind Number Code2	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages o Relevant Figures Appear
		4,933,463	Dandreaux et al.	6/1990	
		4,981,974	Dandreaux et al.	1/1991	
		5,008,367	Dandreaux et al.	8/1991	
		4,946,967	Login et al.	8/1990	
		4,987,210	Login et al.	1/1991	
		6,248,771	Shenoy et al.	6/2001	
		5,756,450	Hahn et al.	5/1998	
		5,902,606	Wunderlich et al.	5/1999	
				<u> </u>	

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document		cument	t Name of Patentee	Date of Publication	Pages, Columns, Lines,	T
Examiner Initials*	Cite No.1	Office3	Number4	Kind Code5	or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
		- T						T6
								L
	_							
			•					<u> </u>
							-	
								$\vdash$

Examiner	Date	
Signature		
Oignature	Considered	

¹Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁰Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box $\rightarrow$	+
-----------------------------------------------------------	---

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 3

Complete if Known

Application Number 09/975,800

Filing Date October 11, 2001

First named Inventor Kinam Park

Group Art Unit

Examiner Name

Attorney Docket Number 368-014

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Examiner Cite T6 publisher, city and/or country where published. NICOLAOU, K. et al. "Design, synthesis and biological activity of protaxols," Nature, 1993, 364: 464-466. PENDRI, A., et al. "Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug," Anti-Cancer Drug Design, 1998, 13: 387-395. TAVARE, N. et al. "Solubilities of 6-aminopenicillanic acid and phenoxyacetic acid in hydrotrope solutions," J. Chem. Eng. Data, 1996, 41: 1196-1202. MULLER, B. et al. "Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs," J. Pharm. Sci., 1991, 80: 599-604. GRAZIANO, G. "On the solvent isotope effect in hydrophobic hydration," J. Phys. Chem. B, 2000, 104: 9249-9254. KUMAR, M. et al. "Effect of hydrotropes on solubility and mass transfer coefficient of methyl salicylate," J.Chem.Eng. Data, 2000, 45: 419-423. SRINIVAS. V., et al. "When does the switch from hydrotropy to micellar behavior occur?" Langmuir, 1998, 14: 6658-6661 DHARA, D. et al., "Effect of hydrotropes on the volume phase transition in poly(N-isopropylacrylamide) hydrogel," Langmuir, 1999, 15: 930-935. SALEH, A., et al., "Solubilization of water by hydrotropic salts," J. Pharm.Sci., 1986, 75: 644-647. COFFMAN, R., et al., "Effect of nicotinamide and urea on the solubility of riboflavin in various solvents," J.Pharm.Sci., 1996, 85: 951-954. SERAJUDDIN, A. "Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs," J. Pharm. Sci., 1999, 88: 1058-ALKAN-ONYUKSEL, H. et al. "A mixed micellar formulation suitable for the parenteral administration of taxol," Pharm.Res., 1994, 11: 206-212. SHARMA, A. et al. "Novel taxol formulations: preparation and characterization of taxol-containing liposomes," Pharm. Res., 1994, 11:889-896. MANI, S., et al. "Phase I clinical and pharmacokinetic study of oral 9aminocamptothecin (NSC-603071)," Cancer Chemother. Pharm., 1998, 42: 84-87.

Examiner		Date	
Signature	-	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

JAN 3 1 2002 SERVER TRADEMARY

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached

	Please type	a plus	sign (+) inside this box $\rightarrow$ +		PTO/SB/08B ()	10-96
_		and or	ork Reduction Act of 1995, no person MB control number.	Patent and Tradomark Office	se through 10/31/99. OMB 065	1-003
1	Substitute ro	or form	1449B/PTO	Con	pplete if Known	
1	70.50		A===0.1.================================	Application Number	09/975,800	
1	INFC	JKM/	ATION DISCLOSURE	Filing Date	October 11, 2001	
1	STA	TFM	ENT BY APPLICANT	First named Inventor	Kinam Park	
1			many sheets as necessary)	Group Art Unit		
春	Sheet 3	30 03 1		Examiner Name		
L	A leet 3		of 3	Attorney Docket Number	368-014	
۲	<u> </u>		OTHER PRIOR			
Į	<del>!:/</del>		OTHER PRIOR ART-NON PA	ATENT LITERATURE	DOCUMENTS	
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).				when appropriate), title of the item e(s), volume-issue number(s),		
			69-88.	f solid dispersions," Pharn	n. Acta Helv., 1986, 61:	T6
			LEUNG, S. et al., "Polymeric napoptotic regression of androge	nicellar paclitaxel phosphon- n-independent LNCaP pro	orylates bcl-2 and induces	
L			Prostate, 2000, 44: 156-163.			
			CHIOU, W., et al., "Pharmaceu Pharm. Sci., 1971, 60: 1281-130	02.		
	1		FLOYD, A. G. et al. "7. Injectal	ble emulsions and suspens	sions." Pharmaceutical	
			Dosage Forms: Disperse System New York, NY	<u>1s</u> . 1998, pp. 261-318, Vo	I. 2, Marcel Dekker, Inc.,	
	İ		MACHERAS, P., et al., "4. Sup	ply of the gastrointestinal	fluids with drug,"	-

Biopharmaceutics of Orally Administered Drugs. 1995, pp. 35-87, Ellis Horwood,

MULLER, R. H. et al., "9. Nanosuspensions," Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, 1998, pp. 149-174, Medpharm Scientific

HABIB, M. J., et al. "2. Fundamentals of solid dispersions," Pharmaceutical Solid Dispersion Technology, 2001, pp. 7-35, Technomic Pub. Co., Inc., Lancaster, PA MARTIN, A., et al., Physical Pharmacy. Physical Chemical Principles in the Pharmaceutical Sciences, 1993, pp.272-273, 4thed, Lea & Febiger, Philadelphia, PA YALKOWSKY, S., Solubility & Solubilization in Aqueous Media, 1999, p. 429,

LOBENBERG, R., et al., "9. Solubility as a limiting factor to drug absorption," Oral Drug Absorption. Prediction and Assessment, pp. 137-153, Marcel Dekker,

Examiner		
Signature	Date	
*EXAMINER: Initial if reference considered, whether a	Considered	
*EXAMINER: Initial if reference considered, whether or citation if not in conformance and not considered. Include:	ude copy of this form with next communication	; Draw line through to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

New York, NY.

Inc., New York, NY

Publ., Stuttgart, Germany

ACS Publ., Washington, DC

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.